Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study
Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study
复制标题
DOI：
10.1111/j.1600-0501.2008.01665.x
复制
发表时间：
2009-08-01
影响因子：
4.3
通讯作者：
Koyano, Kiyoshi
中科院分区：
文献类型：
--
作者：
Jinno, Yohei;Ayukawa, Yasunori;Koyano, Kiyoshi
目的HMG-CoA还原酶抑制剂（他汀类药物）广泛应用于高脂血症的治疗。以前的研究表明，他汀类药物刺激骨形态发生蛋白-2（BMP-2）的表达，并导致骨形成。本研究的目的是评估是否peroxidase注射他汀类药物与一种新的他汀类药物输送系统实现垂直bone augmentation.Material和methodsAs实验组，atelocollagen-alpha-tricalcium phosphate（α TCP）复合材料含有3.3毫克（低剂量）或6.7毫克（高剂量）的氟伐他汀皮下注射（一枪）在大鼠的颅骨骨膜。然后在注射后1、2和4周处死动物。通过组织形态测量程序评估垂直增强骨，即，结果对照组大鼠颅骨未见新生骨形成。相反，在实验组中，在先前存在的颅骨上可以看到大量新形成的骨。观察到新形成的骨与先前存在的骨直接接触。在整个观察过程中，实验组的NBT显著高于对照组（P < 0.05）。在观察的最后阶段（4周），NBT为66.7%（低剂量组）和59.7%（高剂量组），而对照组为1%-16.3%。在实验组中，BD以时间依赖的方式显著增加。ConclusionPerglutinate应用氟伐他汀（一次注射）与α TCP和胶原的复合物具有很大的潜力，以增加骨的高度。氟伐他汀在注射给药系统中的垂直骨增量：大鼠研究。Res. 20，2009; 756-760.doi：10.1111/j.1600-0501.2008.01665.x.
ObjectivesHMG-CoA reductase inhibitors (statins) are widely used for hyperlipidemia. Previous studies demonstrate that statins stimulate bone morphogenetic protein-2 (BMP-2) expression and lead to bone formation. The aim of this study was to evaluate whether percutaneously injected statin with a novel statin delivery system achieved vertical bone augmentation.Material and methodsAs experimental groups, atelocollagen-alpha-tricalcium phosphate (alpha TCP) composites containing 3.3 mg (low dose) or 6.7 mg (high dose) of fluvastatin were injected (one shot) subcutaneously over the calvarial periosteum of rats. The animals were then sacrificed 1, 2, and 4 weeks after injection. Vertically augmented bone was assessed by histomorphometric procedures, i.e., by measuring new bone thickness (NBT) and bone density (BD).ResultsIn control groups, no newly formed bone could be seen over the calvarial bone. In the experimental groups, in contrast, a large amount of newly formed bone could be seen over the preexisting calvarial bone. The newly formed bone was seen to be in direct contact with the preexisting bone. During the entire observation, significant NBT was observed in the experimental groups (P < 0.05). At the final stage of observation (4 weeks), NBT was 66.7% (low-dose group) and 59.7% (high-dose group), while they were from 1% to 16.3% in the control groups. In the experimental groups, BD significantly increased in a time-dependent manner.ConclusionPercutaneously applied fluvastatin (one shot) with a composite of alpha TCP and collagen has great potential to augment the height of the bone.To cite this article:Jinno Y, Ayukawa Y, Ogino Y, Atsuta I, Tsukiyama Y, Koyano K. Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study.Clin. Oral Impl. Res. 20, 2009; 756-760.doi: 10.1111/j.1600-0501.2008.01665.x.